Please login to the form below

Halozyme Therapeutics

This page shows the latest Halozyme Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Halozyme to resume pancreatic cancer study

There was relief for Halozyme Therapeutics after it was told it can resume a clinical study investigating a potential treatment for pancreatic cancer. ... With the trial now back underway, Halozyme said it intends to recruit another 100 patients to add

Latest news

Halozyme halts pancreatic cancer trial

Halozyme halts pancreatic cancer trial. The biopharma company is investigating PEGPH20’ s links to blood clot. ... Halozyme Therapeutics has paused a phase II trial of its investigational pancreatic cancer drug in order to assess the candidate's safety.
Baxter re-files HyQvia for immunodeficiency in US

HyQvia - which uses delivery technology developed by Halozyme Therapeutics - is a combination of human normal immunoglobulin (IG) and recombinant human hyaluronidase which can be delivered by subcutaneous injection every three to ... Meanwhile, for
Roche wins EU approval for injectable Herceptin

Roche developed subcutaneous Herceptin using recombinant human hyaluronidase technology developed by US-based biopharma company Halozyme Therapeutics.
Roche's Perjeta backed in EU for breast cancer

Roche is also developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of trastuzumab - partnered with Halozyme Therapeutics - that is also in the latter stages of development.
Roche's T-DM1 activity in breast cancer "outstanding"

Roche is developing additional products intended to protect its Herceptin franchise, including a subcutaneous formulation of the drug partnered with Halozyme Therapeutics which is scheduled for filing later this year.

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Pharma deals in June 2015

Acquisition - company. 1, 470. Halozyme Therapeutics/ AbbVie. ENHANZE platform technology to improve sc delivery (up to 9 targets). ... NewCo formation, collaboration. 760. Unum Therapeutics/ Seattle Genetics. Antibody-coupled T-cell receptor technology
Deal Watch table for December 2014

Expansion of collaboration/ amended agreement. 675. Halozyme Therapeutics / J&J. ENHANZE rHuPH20 delivery technology for up to 5 targets. ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy products
Pharma deals during December 2014

Switching to drug delivery technologies, J&J/Janssen entered into a global licence with Halozyme Therapeutics to access Halozyme's ENHANZE technology, which is designed to enable subcutaneous administration of injectable ... Subcutaneous formulations of

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Amgen veteran Kurt Gustafson joins Spectrum as CFO

He joins Spectrum from fellow US biotech Halozyme Therapeutics, where he served as VP and chief financial officer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Account Manager – Med Comms – London: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Editorial Director – Medical Education – Oxford: Negotiable

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager or AD - Medical Communications: Salary TBC

Senior Medical Writer: Great salary and bebefits

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Programme Executive: Salary TBC

Senior Medical Writer: Great salary and benefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Account Manager – Med Comms – Kent: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Manager / Account Director: Great salary and bebefits

Scientific Director: Great salary and bebefits

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Subscribe to our email news alerts

PMHub

Add my company

VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...